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Abstract: The field of prostate oncology has continued to change dramatically. It has truly 
become a field that is intensely linked to molecular genetic alterations, especially DNA-repair 
defects. Germline breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2) mutations 
are implicated in the highest risk of prostate cancer (PC) predisposition and aggressiveness. 
Poly adenosine diphosphate ribose polymerase (PARP) proteins play a key role in DNA repair 
mechanisms and represent a valid target for new therapies. Olaparib is an oral PARP inhibitor 
that blocks DNA repair pathway and coupled with BRCA mutated-disease results in tumor 
cell death. In phase II clinical trials, including patients with advanced castration-resistant PC, 
olaparib seems to be efficacious and well tolerated. Waiting for randomized phase III trials, 
olaparib should be considered as a promising treatment option for PC.
Keywords: prostate cancer, metastatic disease, castration resistant, BRCA, DNA-repair, 
PARP, olaparib
Introduction
Prostate cancer (PC) is a frequently diagnosed cancer worldwide, with 14% of total 
new cancer cases and 6% of the total cancer deaths in males.1 PC is characterized by 
a wide spectrum of clinical behavior that spans from indolence to a very aggressive 
and lethal disease.2 Durable control of advanced PC represents a public health need, 
and an in-depth analysis of the genomic landscape seems to be paramount. In fact, PC 
is also one of the most heritable human malignancies, suggesting that approximately 
50% of the inter-individual variation in PC risk is due to genetic factors. Family history 
of PC is presently viewed as a strong risk factor for the disease development.3 It has 
been observed that PC shares genetic variants with other types of familial malignan-
cies, especially with breast and ovarian cancers (OCs).4 Genome-wide association 
studies have identified more than 70 common variants explaining about 30% of the 
excess familial PC risk.5 Deleterious mutations in DNA repair pathways, including 
breast-cancer susceptibility gene 1 (BRCA1) and breast-cancer susceptibility gene 2 
(BRCA2) mutation carries, predispose to a more aggressive clinical course disease 
and worst cancer-specific survival.6,7 For instance, patients with germline mutations in 
BRCA2 have a 8.6-fold increased risk of developing PC by age 65, with an absolute 
risk of 15%.8 However a “BRCAness” phenotype should be delineate, including a 
large spectrum of somatic mutation in genes involved in DNA repair processes, to 
research a treatment tailored to “BRCAness” status.
In fact, men with metastatic PC and DNA-repair gene mutations have been 
reported to exhibit sustained responses to inhibitors of poly adenosine diphosphate 
ribose polymerase (PARP) and platinum-based chemotherapy.9 Normal cells are less 
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subjected to DNA damage than tumor cells and, therefore, 
less influenced by inhibitors of DNA repair mechanisms. 
The nuclear PARP enzymes are physiologically involved in 
multiple aspects of DNA repair and transcription regulation. 
In BRCA1/2-deficient cells, and thus in cells with defective 
DNA repair mechanisms, PARP inhibition translates into 
selective cell death. Consistent with this assumption, the 
PARP inhibitor olaparib (Lynparza™; AstraZeneca) has 
been tested in several solid tumor types occurring in patients 
with germline mutation in BRCA1 and/or BRCA2, and it 
has recently been approved for treating OCs with BRCA1/2 
mutations.10 Based on the efficacy demonstrated in platinum 
chemotherapy-sensitive OC patients, PARP inhibitor therapy 
is being rapidly added to PC clinical trial practice, but how to 
best incorporate it with existing therapies remains an urgent 
need. This review provides highlights in pharmacology 
profile, clinical efficacy, tolerability and role in therapy 
of olaparib, to potentially offer a more tailored treatment 
approach in PC patients in the near future.
DNA repair mechanisms
DNA damage can be acquired in cells over time through 
exposure to exogenous chemicals and physical agents or 
endogenous reactive metabolites including reactive oxygen 
and nitrogen species. Efficient and correct repair of DNA 
damage is critical for cellular survival. DNA repair can be 
grouped into single-strand breaks (SSBs) and double-strand 
breaks (DSBs). SSBs include base-excision repair, nucleotide 
excision repair, and mismatch excision repair, whereas DSBs 
comprise non-homologous end-joining (NHEJ) and homolo-
gous recombination (HR) mechanisms.
Single-strand breaks
Most frequently, DNA damage is reduced to SSBs. The 
repair of base damage is initiated by the glycosylate, a DNA 
repair enzyme, which recognizes and excises damage bases. 
The subsequent apyrimidinic site is recognized by an endo-
nuclease enzyme that nicks the DNA adjacent to the lesion. 
Then an exonuclease removes the abasic site and the gap 
is patched by DNA polymerase, using the opposite DNA 
strand as a template.
The nucleotide excision repair is mediated by structure-
specific endonucleases, which identify more generalized 
DNA structural distortion. These repair proteins incise the 
DNA strand on both sides of the complex lesion, activat-
ing the repair process, which is therefore similar to that of 
base excision.
The specificity of mismatch excision repair is primarily 
for base–base mismatches and insertion/deletion loops caused 
by DNA polymerase during DNA replication and recombina-
tion. It consists of mismatch recognition and assembly of the 
repair complex, degradation of the error-containing strand, 
and repair synthesis.11,12
Double-strand breaks 
NHEJ represents the dominant repair pathway. The DNA-
dependent protein kinase binds the ends of double-stranded 
DNA and then recruits the catalytic subunit of DNA-dependent 
protein kinase to the ends. Thus NHEJ simply restores DNA 
integrity by joining the two broken ends together.13,14 On the 
other hand, HR is a more accurate repair process, error-free, 
and most active in the late S/G2 phases of the cell cycle.15 
It involves the use of the intact sister chromatid and a vast 
number of proteins, including RAD51, BRCA1, BRCA2, 
and ATM. Repair is initiated by resection of a DSB. Strand 
invasion is followed by DNA synthesis and the second DSB 
end is, therefore, captured to resolve in subsequent DNA 
synthesis and ligation.16
Defective processes linked to PC
Synthetic lethality
The concept of synthetic lethality refers to the combination 
of two entities to form something new. It occurs when the 
simultaneous inactivation of two genes results in cellular 
death.17 In recent years, synthetic lethality has attracted 
researchers’ attention because it may explain the sensitivity 
of tumor cells to certain drugs that act in specific DNA repair 
processes. The large potential of synthetic lethality-based 
cancer therapy is mainly represented by the combination of 
germline BRCA1/2 mutations and chemical inhibition of the 
DNA repair enzyme PARP.
BRCA1 and BRCA2 are tumor suppressor genes that 
mainly contribute to repair DNA damage. They map on two 
different chromosomes, 17q21 and 13q12.3, respectively.18 
BRCA1 and BRCA2 form complexes that activate the repair 
of DSBs in response to DNA damage. Secondary to DSBs, 
BRCA1 is phosphorylated by ataxia-telangiectasia mutated 
(ATM) kinase and, in cooperation with BRCA2 and RAD51 
protein, activates DNA repair through HR.
By contrast, PARP enzyme detects SSBs and recruits 
different pathways that use the complementary undam-
aged strand to repair damages and correct mutations. 
When PARP enzymes are pharmacologically inhibited, the 
relatively innocuous SSBs cannot be repaired and become 
lethal when occurring in a cell in which HR pathway of 
DNA repair is lacking (synthetic lethality). Therefore, 
germline mutations of BRCA genes or somatic muta-
tions in genes involved in HR, such as ATM and RAD51, 
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can determine loss of DNA repair ability, resulting 
ultimately in cancer onset.
Focus on PC
It is important to recognize that not only BRCA1 and 
BRCA2 but also other genes encoding proteins that are 
involved in DNA repair are essential in generating BRCA-
ness phenotype in PC. Expanding the focus to other DNA 
repair/recombination genes, both ATM and RAD51 muta-
tions can confer sensitivity to PARP inhibitors. The Stand 
Up To Cancer–Prostate Cancer Foundation (SU2C-PCF) 
castration-resistant PC project identified aberrations of 
DNA-repair genes, including BRCA1, BRCA2, and ATM, 
at substantially high frequencies (19.3%).19 Mateo et al9 data 
showed tumor aberrations in DNA-repair genes, mainly 
BRCA2, ATM, and BRCA1, in 33% of cases. Pritchard 
et al2 recruited 692 men with documented metastatic PC. 
DNA-repair gene mutations were identified in 11.8% cases. 
Of the 20 genes analyzed, pathogenic germline mutations 
were found in 16 genes, including BRCA2 (5.3%), ATM 
(1.6%), BRCA1 (0.9%), and RAD51 (0.4%).
Profile of olaparib
Olaparib is a potent PARP inhibitor that induces synthetic 
lethality in BRCA1/2-deficient tumor cells. In December 2014, 
the European Medicines Agency approved olaparib to 
be used in the maintenance therapy of patients affected 
by BRCA1/2-mutated OC responding to platinum-based 
chemotherapy; furthermore, in the US, olaparib also has 
received accelerated approval by the US Food and Drug 
Administration (US FDA) as a monotherapeutic agent for 
patients with deleterious or suspected deleterious germline 
BRCA-mutated advanced OC and who have been treated with 
three or more prior lines of chemotherapy.10 As observed in 
OC, PARP inhibitors appears to induce clinical responses 
in patients with metastatic PC expressing HR DNA-repair 
defects. In fact, olaparib has been designed to target DNA 
repair pathway. If PARP enzyme is inhibited, SSB cannot 
be repaired efficiently and causes cumulative DNA damage. 
The PARP inhibition, in addition to the deficiency in the HR 
pathway that occurs in BRCA-mutated PC cells, translates 
into tumor cells death.
Mechanism of action
Physiologically, PARP is a nuclear enzyme complex dis-
covered in the early 1970s. The PARP family comprises a 
group of 17 proteins that function in several cellular mecha-
nisms, including transcription, DNA replication, and DNA 
repair. Of the PARP family, PARP1 and PARP2 are the 
best-characterized subtypes and their function is paramount 
to maintain the genomic integrity in the base-excision repair 
pathway.20 When damage is limited to one of the DNA 
strands, PARP enzymes are involved to coordinate DNA 
repair through base excision. It is a zinc-finger DNA-binding 
protein that detects specifically DNA SSBs. At the site of 
breakage, PARP catalyzes the transfer of the ADP-ribose 
moiety from NAD+ substrate to several protein acceptors 
involved in DNA metabolism and activates the base-excision 
machinery to repair the SSB.21 Inhibition of PARP enzymes 
would determine a collapse in the base-excision repair 
pathway, resulting in the accumulation of DNA damage. In 
normal cells, PARP inhibition would be of no significant 
importance because of efficient DSBs repair mechanisms. 
However, in cells with deficient HR, such as BRCA-mutated 
PC cells, PARP inhibition would be lethal for tumor cells.
As a consequence, PARP inhibitors would kill tumor 
cells selectively, with minimal effects on healthy cells with 
normal gene function.
Pharmacology
Olaparib is available as capsules for oral administration. 
Following oral administration, olaparib is rapidly absorbed, 
with peak plasma concentrations (Cmax) typically achieved 
1–3 h thereafter.10 Mean apparent volume of distribution, 
mean apparent plasma clearance, and mean terminal half-
life are 40.3 L, 4.55 L/h, and 6.10 h, respectively. Exposure 
increased proportionally with dose at doses up to 100 mg 
twice daily but increased in a less than proportional fashion 
at higher doses.22 Based on safety assessments, the maximum 
tolerated dose of olaparib is identified as 400 mg twice daily. 
When given at a dosage of 400 mg twice a day orally, the 
estimated Cmax ranged from 1.45 to 11.0 μg/mL, with an 
area under the plasma concentration-time curve from 0–12 h 
ranged from 6.56 to 122 μg⋅h/mL. Olaparib is primarily 
metabolized by cytochrome P-450 isozyme 3A. Drug-related 
metabolites are eliminated in the urine (35%–50%) and in 
the feces (12%–60%).
Clinical efficacy in PC
Currently, olaparib is undergoing trials to be used in the 
treatment of PC. Results of phase II clinical trials showed that 
patients with BRCA1/2-mutant PC are likely to potentially 
respond to PARP inhibitors. Details are presented in Table 1. 
To date, there are no published and ongoing randomized 
phase III trials evaluating the use of olaparib in PC.
The Trial of PARP Inhibition in Prostate Cancer 
(TOPARP) trial is a two-part adaptive-design phase II trial 
that aims to evaluate olaparib in patients with advanced 
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castration-resistant PC.23 Overall, 50 patients were enrolled 
in part A (TOPARP-A) trial.9 The primary outcome was 
to evaluate the response rate of olaparib tablets at a dose 
of 400 mg twice a day in this setting of patients. Response 
was defined as objective response by Response Evaluation 
Criteria in Solid Tumors (RECIST), prostate-specific anti-
gen (PSA) decline of $50%, or a confirmed reduction of 
circulating tumor cell count from $5 cells/7.5 mL of blood 
at baseline to ,5 cells/7.5 mL. Overall, 33%, 22%, and 
29% of patients had an objective response, reductions in the 
PSA level of 50% or more and confirmed reduction in the 
circulating tumor cell count to ,5 cells/7.5 mL, respectively. 
Patients with aberrations in DNA-repair genes (33%) had a 
significantly higher response rate (P,0.001) than those with 
no defects. Of interest, of these patients with DNA repair 
mutations, 88% showed a response to olaparib, indicating that 
the specificity for response in this setting of patients was 94%. 
In addition, olaparib resulted in improved progression-free 
survival (PFS) (median PFS: 9.8 months versus 2.7 months; 
P,0.001) and overall survival (OS) (median OS, 13.8 months 
versus 7.5 months; P=0.05) among patients with DNA-repair 
defects in their tumor cells. Currently, patients’ recruitment 
continues for the second part of the trial (TOPARP-B).
A multicenter phase II study was designed to assess the 
efficacy and safety of olaparib in confirmed genetic BRCA1/2 
mutation in different malignant solid tumors.24 In total, 
298 patients were enrolled, of whom 8 had metastatic PC. PC 
patients received oral olaparib 400 mg twice a day. Tumor 
response rate was assessed according to RECIST and it was 
50% (95% confidence interval 15.7–84.3) in those with PC. 
Median duration of response was 372 days, and median 
time to onset of response was 54.5 days. PFS and OS were 
7.2 months and 18.4 months, respectively.
Ongoing trials
Studies evaluating PARP inhibitors in combination with other 
PC therapies have been proposed. A randomized phase II trial 
(NCT01972217) compares the efficacy, safety, and tolerability 
of olaparib versus placebo when associated with abiraterone 
treatment in patients with metastatic castration-resistant PC 
who have received prior docetaxel-based chemotherapy.25
A phase I/II study (NCT02484404) of the anti-programmed 
death ligand-1 antibody MEDI4736 in combination with 
olaparib and/or cediranib (vascular endothelial growth factor 
inhibitor) for different advanced solid tumors, including PC, 
tests the safety of this drugs combination.26
Table 1 Olaparib for the treatment of prostate cancer (PC)
Trials Study design Eligibility Study arms Primary endpoint Results
TOPARP9 Phase ii Advanced castration-
resistant PC
Oral olaparib* RR RR: 33%
PFS**: 9.8 mo vs 2.7 mo***
     OS**: 13.8 mo vs 7.5 mo***
Kaufman et al24 Phase ii BRCA1/2-mutated advanced 
solid tumor (PC cohort, n=8)
Oral olaparib* RR RR in PC: 50%
PFS in PC: 7.2 mo
     OS in PC: 18.4 mo
NCT0197221725 Randomized 
phase ii
Metastatic castration- 
resistant PC
Olaparib + abiraterone Safety PFS, RR, OS
(ongoing)
   Placebo + abiraterone   
NCT0248440426 Phase i/ii Advanced or recurrent 
solid tumor
PDL-1 + olaparib Safety Recommended dose
(ongoing)
PDL-1 + cediranib
   PDL-1 + olaparib + cediranib   
Keynote-36527 Phase i/ii Metastatic castration- 
resistant PC 
Pembrolizumab + olaparib Safety Adverse events, RR, OS
(ongoing)
Pembrolizumab + docetaxel
   Pembrolizumab + enzalutamide   
NCT0289391728 Randomized 
phase ii
Metastatic castration- 
resistant PC 
Olaparib + cediranib PFS PFS, RR, OS
(ongoing)
   Olaparib + placebo   
NCT0232499829 Phase i intermediate-/high-risk PC Olaparib Degree PARP 
inhibition
Adverse events
(ongoing)
Notes: *400 mg twice daily, continuously on a 28-day cycle; **biomarker positive versus biomarker negative; ***P#0.05.
Abbreviations: RR, response rate; PFS, progression-free survival; OS, overall survival; mo, months; PDL-1, programmed death ligand-1; PARP, poly(ADP-ribose) 
polymerase.
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The Keynote-365 study is a phase Ib/II trial (NCT02861573) 
that analyzes three different combination therapies in meta-
static castration-resistant PC and cohort A will receive 
olaparib (400 mg twice a day) plus pembrolizumab.27 The 
purpose of this study is to assess the safety and efficacy of 
these combination therapies.
A randomized phase II trial (NCT02893917) studies 
how well olaparib with or without cediranib works in treating 
patients with metastatic hormone-resistant PC.28 The primary 
end point is to assess the clinical activity of this drugs’ 
combination.
Lastly, there is a phase I study (NCT02324998) inves-
tigating the feasibility and tolerability of a short course of 
neoadjuvant treatment with olaparib given prior to radical 
prostatectomy in patients with early, localized, intermediate, 
and high-risk PC.29 Primary objective is to determine the 
pharmacodynamic biomarker effects of olaparib in this 
setting of patients.
Safety
Tolerability
Globally the tolerability profile of PARP inhibitors is 
substantially manageable. Hematologic toxicity, including 
anemia, thrombocytopenia, and neutropenia, and gastroin-
testinal disorders, primarily nausea and vomiting, are the 
most commonly reported adverse events. Fatigue is also 
reported. Rarely, olaparib therapy may increase the risk of 
developing myelodysplastic syndrome and acute leukemia, 
but this risk must be further characterized, especially in PC. 
In fact, there are no cases of myelodysplastic syndrome and 
acute leukemia reported in PC series. However, at the time 
of the FDA approval in OC, among 2,618 patients exposed 
to olaparib, myelodysplastic syndrome and acute leukemia 
occurred in 0.8% of cases.10
In the TOPARP-A trial, the median duration of olaparib 
treatment was 12 weeks, and the average delivered-dose 
intensity was 87%.9 Anemia (20%) and fatigue (12%) were 
the most frequent grade $3 drug-related effects, in keeping 
with other trials of olaparib. Overall, 26% of cases required 
a reduction in the dose of olaparib and anemia was the most 
common indication for dose reduction. Olaparib was perma-
nently discontinued in 6% cases due to adverse events.
Resistance
Not all patients with DNA repair deficiency will respond 
to olaparib. Several resistance mechanisms that restore 
defective HR have been proposed, but, at present, which 
mechanisms contribute to PARP inhibition resistance in PC 
is still unclear.30 Both ongoing and future trials could detect 
secondary mutations associated with olaparib resistance.
Patient-focused perspectives
Today, parameters for patient’s quality of life (QoL) should 
be considered as paramount in the clinical evaluation to 
significantly improve treatment algorithm.
Olaparib represents an attractive therapy, considering 
that it has a generally more favorable toxicity profile than 
cytotoxic chemotherapy. Data regarding the impact of 
olaparib on QoL are very limited, and further investigations 
are needed. At this time, QoL data are restricted to secondary 
endpoints in the phase II trials in OC, in which olaparib versus 
placebo resulted in equal or better QoL rates.31,32
Survival benefit may be considered as a surrogate of 
QoL improvement, sparing patients from the symptoms of 
progressive disease, avoiding additional therapies and their 
attendant toxicities, and preventing the psychological burden 
and uncertainty that come with disease progression. How-
ever, it should be important to consider QoL assessment in 
future studies design in PC.
Conclusion
Currently, there is a clinical need and urgency for additional 
treatments that are well tolerated and that can improve 
outcomes in PC patients, especially in those with metastatic 
castrate-resistant disease.
While the use of olaparib is currently restricted to the treat-
ment of OC, ongoing studies will focus on expanding its role 
in the management of other solid tumors, including PC.
Regarding PC, olaparib warrants further investigation 
in phase III trials aimed at confirming earlier phase II data. 
However, if phase III trials fail to show improvement in 
survival among patients with metastatic castration-resistant 
PC and DNA-repair defects, definitive conclusions cannot 
be reached. Based on available data, PARP inhibition seems 
feasible, but only in patients with appropriate biomarkers 
status. The preselection of patients based on proper molecular 
profile should be paramount, as we move toward the new era 
of targeted therapies. Moreover, the optimal combinations, 
as well as the sequence of treatments, should have a better 
understanding. Therefore, it is too early to establish the real 
impact of olaparib therapy in PC, but if future trials will 
confirm its efficacy, olaparib might represent an important 
step toward personalized medicine for PC.
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